PSE (Pseudoephedrine)

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the below statement today following Tennessee Governor Bill Lee's recent signing of Senate Bill 2048 into law, legislation that raises the monthly purchase limit for common over-the-counter (OTC) cold and allergy medications containing the ingredient pseudoephedrine (PSE) from 5.76 grams per month to 7.2 grams, allowing access to a full 30-day supply per month. The bill also raises the annual purchase limit to 43.2 grams, which is a 40% increase from the current limit of 28.8 grams.

In recent years, the issue of consumer data privacy has become increasingly important as technology continues to advance, and more personal information is collected and shared online. Despite the growing concerns over data privacy, the federal government has yet to enact comprehensive legislation addressing the issue. This lack of federal action has prompted many states to take matters into their own hands and introduce their own data privacy laws to protect their residents.

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the below statement today following the adoption of Kentucky House Bill 386 into law, legislation that will eliminate the state’s annual purchase limit for common over-the-counter (OTC) cold and allergy medications containing the ingredient pseudoephedrine (PSE), which is currently the most restrictive yearly limit nationwide at 24 grams, or roughly a three-month supply.

Here are the Federal Register notice summary excerpts that might be of interest to you or others within your organization. Please see notices for complete details.

Oregon has repealed a 15-year-old law that banned OTC sales of certain medicines for colds and allergies containing PSE.

In a major victory for consumer health, today Mississippi has repealed an 11-year-old law that banned over-the-counter (OTC) sales of certain medicines for colds and allergies containing the decongestant pseudoephedrine (PSE).